Oncology is the largest pharmaceutical therapeutic area, and big pharma is investing billions of dollars in search of the elusive cancer cure. With all this investment and innovation, will we ever see a universal cancer cure? Lets find out.
Oncology treatment has come a long way since the advent of chemotherapy in the 1940s. There have been tremendous advancements in the field of oncology, especially over the last two decades, resulting in improved quality of life and survival rates. There are more than1,300medicines and vaccines in development to tackle cancer, as of January 2021 (source: PhRMA). Many innovative therapies have been launched and pharmaceutical companies continue to invest significantly in oncology research to advance the cancer treatment market.
Cancer has undergone huge changes in the last five years as new treatments that harness the immune system to restore the balance between cancer cells and healthy cells have been extensively evaluated. Drugs like PD-1/L1 inhibitors have revolutionised the treatment of late-stage melanoma, lung cancer and renal cancer, dramatically improving five-year survival rates, said Daniel Chancellor, Thought Leadership Director, Informa Pharma Intelligence, UK.
We also now have genetically modified cell therapies that produce impressive response rates for advanced forms of blood cancer. More generally, cancer populations are being defined not just by the tumor location but by an ever-growing list of biomarkers that have relevance for prognosis and the selection of appropriate targeted therapies. Chemotherapy is still an essential part of cancer treatment, but is increasingly being displaced or supplemented by innovative new cancer drugs, added Chancellor.
The focus of cancer treatment is rapidly shifting from a traditional one-size-fits-all approach to precision medicine, tailored treatments for individual patients. Lets look at the next wave of innovations making headlines in the cancer space:
Next wave of innovations
Liquid biopsy
Until 2020, the US Food and Drug Administration (USFDA) had approved liquid biopsy tests for single genes. But in 2020, the US regulator granted two approvals for liquid biopsy NGS (next generation sequencing) companion diagnostic tests for multiple cancers and biomarkers.
These new tests are US Guardant Healths Guardant 360 CDx assay, and FoundationOne Liquid CDx, marketed by Foundation Medicine, USA.
It is worth noting that these are the tests for people already screened for cancer and aren't yet officially approved for first in line cancer screening.
US-based companies such as Thrive, Grail and Singlera Genomics are actively pursuing this technology for cancer screening.
Liquid biopsy is becoming more sensitive and specific. I think in the not too distant future we will be able to detect many of the currently deadly cancers, such as pancreatic, ovarian, brain, etc. at a much earlier stage when they can be cured, said DrIgor Sherman, CEO, Alpha Cancer Technologies, Canada.
Alpha Cancer Technologies Inc. (ACT) is a private clinical stage biotechnology company with products under development in immunotherapy and immuno-oncology. The companys drug products use its proprietary recombinant human alpha fetoprotein (AFP).
Tumor Agnostics
Cancer treatment historically has been developed according to their organ or tissue of origin. But in the last few years, there has been an uptick in tumor agnostic therapies for cancer i.e. where patients will be treated based on the genomic profile of the tumor, without regard to the cancer type or where the cancer started in the body.
The tumour-agnostic approach to cancer treatment offers great potential for growth in the oncology pharmaceuticals market.
On May 23, 2017, the USFDA approved the first ever drug in this segment to pembrolizumab (KEYTRUDA, Merck & Co.) for adult and paediatric patients with unresectable or metastatic, microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) solid tumors. Its worth noting that pembrolizumab was earlier approved for skin and lung cancer.
In June 2020, the USFDA approved another use for pembrolizumab to treat adults and children with unresectable or metastatic solid tumors that have a high tumor mutational burden (TMB-H) and other treatment options offer fewer benefits. Tumour mutational burden is the number of gene changes, or mutations, in a cancer cell.
The first FDA tumour-agnostic approval for a drug not already in use came in 2018, with the approval of US Loxo Oncologys Vitrakvi (larotrectinib), a treatment for adult and paediatric patients whose cancers have a specific genetic feature (biomarker).
At least 10 further tumour-agnostic therapies are in development, based on a range of genetic mutations, according to a report in Cancer World. But whilst tumour-agnostic approaches have attracted a lot of attention, it is still a niche area.
Cell and Gene Therapy
The idea of altering a gene to cure or treat a disease is fairly new, but with the first USFDA approval of Novartis gene therapy Kymriah (tisagenlecleucel) for certain paediatric and young adult patients with a form of acute lymphoblastic leukemia (ALL) in 2017, that concept is now a reality.
And the pace of research and development in cell and gene therapy is increasing. A 2020 PhRMA report on the cell and gene therapy pipeline found 362 therapies in clinical development by biopharmaceutical companies.
As of February 2020, there are nine cell or gene therapy products approved in the US treating cancer, eye diseases and rare hereditary diseases.
Some of the innovative cell therapies in development such as Chimeric antigen receptor Natural Killer (CAR NK) and iPSCs (Induced pluripotent stem cells) are also being explored alongside CRISPR (clustered regularly interspaced short palindromic repeats), a high-precision gene-editing tool, which could be another game-changer in oncology.
Targeted Therapies
New and more specific targeted therapies are being developed by many companies and some of them have already shown very high efficacy. In September 2021, UKs AstraZenecas Enhertu (trastuzumab-deruxtecan) had shown to significantly prolong survival in certain breast cancer patients.
In 2019, the FDA had approved both larotrectinib (Bayer and Partners)and Genentechs entrectinib (Rozlytrek), which are both targeted therapies,to treat adults and children with solid tumors that have a gene alteration known as a neurotrophic receptor tyrosine kinase (NTRK) gene fusion.
Toxicity remains a challenge, but identification of targets that are more specific for cancer cells and not present on normal cells, such as alpha-fetoprotein receptors, offer a possibility of highly effective and non-toxic cancer therapies, said Dr Sherman.
Synthetic lethality is emerging as an important cancer therapeutic paradigm and pharma firms are developing targeted anti-cancer therapeutics based on this. It refers to the simultaneous deactivation of two, non-lethal genes that results in cell death. If specific genes can be deactivated in tumors, drugs that inhibit their synthetic lethal partner genes can target and kill cancer cells without harming healthy cells. Synthetic lethal mechanisms are expected to achieve new breakthroughs in targeted cancer therapy.
Another latest trend in research is to study the microbiome as they can provide ingredients which the cancer cells can use to favour their growth in specific tissues and locations. Researchers have shown that the makeup of the gut microbiome of mice impacts the size and number of their liver cancer tumors. In other studies with human volunteers, researchers are finding more associations. For instance, one research has found that a more diverse microbiome could improve the effectiveness of immunotherapy treatments for skin cancer. Clinical trials are ongoing to learn more about how a healthy microbiome might affect many other types of cancer and related treatments.
Can Cancer be Cured?
Oncology continues to attract the majority of the investment in the pharma space. In 2020, global oncology spending totalled $167 billions. In comparison, costs stood at $74 billions six years earlier in 2014, according to Statista.
Almost half of the cash spent by drug developers on company acquisitions and licensing deals has been directed at oncology over the past five years a sum of around $120 billion, 41 per cent of the total deployed, according to Evaluate Vantage 2021 Preview.
With billions pouring in from investors and governments alike, will we be able to finally find a cure for this disease? Experts are wary about that.
I am not sure if universal cure is around the corner, but I am optimistic that in the next 10 to 20 yearswe should be able to cure a lot more people than is possible today and to provide a good quality of life for a much longer time than today to those we cannot cure, opined Dr Sherman.
Echoing the same sentiments Chancellor said, Lifestyle modifications (healthy diet, exercise etc.) are the closest thing possible that have proven universal risk reduction. But cancer is an inevitable consequence of human biology. If anything, the more investment that goes into cancer, the more evident it is that there is no such thing as a universal cure. The ideal treatment, one that has potential to be curative, has to be as closely matched as possible to the underlying cause(s) that result in the cancer in the first place. Each patient is almost unique in this respect, owing to the precise contribution of lifestyle, environmental and genetic risk factors.
The cancer treatment market is on the verge of a paradigm shift, with gene and cell therapy, precision medicine gaining much more ground. There is a better hope that we are on the cusp of finding a suitable prevention and/or cure for this dreaded disease.
Ayesha Siddiqui
See the rest here:
Reality of universal cancer prevention & cure - BSA bureau
- Signal of Benefit for Stem Cell Therapy in Progressive MS - Medscape - March 7th, 2024
- The Controversies Surrounding Stem Cell Therapy for Autism - The Portugal News - February 24th, 2024
- Benefits of Stem Cell Therapy - News Channel 5 Nashville - February 7th, 2024
- What is Stem Cell Therapy & How It Helps Others - Publicist Paper - January 31st, 2024
- A guide to stem cell therapy in Thailand - Thaiger - January 4th, 2024
- Half of pediatric patients with aHUS benefit from Soliris after... - AHUS News - December 21st, 2023
- Real world analysis on the determinants of survival in primary ... - Nature.com - December 5th, 2023
- The Best Beauty Gifts According To People Who Really Know Skin Care - HuffPost - December 5th, 2023
- The Eyepopping Factory Construction Boom in the US - WOLF STREET - December 3rd, 2023
- Benefit of Neoadjuvant Therapy Illustrated During ESMO Congress ... - Targeted Oncology - December 1st, 2023
- Benefits Outweigh Risks as FDA Inspects CAR-T Cell Therapy ... - Curetoday.com - December 1st, 2023
- Review What Real Cavityn Customers Say About Benefits and Side ... - Seattle Weekly - December 1st, 2023
- 'There is a Scientific Fraud Epidemic' - Slashdot - Slashdot - December 1st, 2023
- 15 Best Hydrating Serums to Soothe Any Skin Type 2023 - Town & Country - December 1st, 2023
- Innovations in Cosmetic Dermatology: A Glimpse into the Future - APN News - December 1st, 2023
- FDA Probes New Cases of Cancer That May Stem From Cancer Cell ... - MedCity News - November 29th, 2023
- Use of plant stem cells in topical formulations on the rise - CosmeticsDesign.com USA - November 29th, 2023
- Stem cell-based treatment controls blood sugar in people with Type ... - EurekAlert - November 29th, 2023
- Biologics Market is projected to grow at a CAGR of 8.5% by 2034: Visiongain - Yahoo Finance - November 29th, 2023
- Scientists devise new technique that can pinpoint the causes and ... - EurekAlert - November 29th, 2023
- Global Advanced Therapy Medicinal Products Market is on the brink ... - PharmiWeb.com - November 29th, 2023
- Introducing Orgavalue - The 2023 EIT InnoStars Awards winner - EU-Startups - November 29th, 2023
- Episode 160: Euan Ashley discusses precision medicine and the ... - IHMC - November 29th, 2023
- Is Phenq Right For You? Review The Facts Before Making a ... - Vashon-Maury Island Beachcomber - November 27th, 2023
- Cavityn Reviews - Does It Work? Cheap Scam or Effective ... - The Daily World - November 25th, 2023
- Trend Hunting With Beautystreams At Cosmoprof Asia 2023 - BeautyMatter - November 25th, 2023
- FDA Considers First CRISPR Gene Editing Treatment That May ... - Slashdot - November 25th, 2023
- How Do Plants Determine Where the Light Is Coming From? - Lab Manager Magazine - November 25th, 2023
- Deaths From Coal Pollution Have Dropped, But Emissions May be ... - Slashdot - November 25th, 2023
- Stem cell-based therapies for stroke in newborns - Cochrane - November 23rd, 2023
- Dr Leslie on Outpatient CAR T-Cell Therapy Programs for ... - OncLive - November 23rd, 2023
- Human Milk-Based Therapy May Be Beneficial in Blood Cancers - Curetoday.com - November 23rd, 2023
- Oncological Horizons: The Synergy of Medical and Surgical ... - Cureus - November 23rd, 2023
- Human and environmental safety of carbon nanotubes across their ... - Nature.com - November 23rd, 2023
- Immix Biopharma to Host KOL Event to Discuss its BCMA-Targeted ... - BioSpace - November 23rd, 2023
- #HearTheMarsdenKids call on NHS London to reconsider cancer ... - Metro.co.uk - November 23rd, 2023
- Diagnosis and Management of Cardiovascular Risk in Patients with ... - Dove Medical Press - November 23rd, 2023
- BioLineRx Reports Third Quarter 2023 Financial Results and ... - PR Newswire - November 21st, 2023
- Why our Award Winners Beauty Box is the ultimate beauty gift (for ... - Yahoo Singapore News - November 21st, 2023
- SightCare Reviews - Is Official Website for Sight Care Legit to Try or ... - Vashon-Maury Island Beachcomber - November 21st, 2023
- Legend Biotech Reports Third Quarter 2023 Results and Recent ... - StreetInsider.com - November 21st, 2023
- Lorenzo's Oil: Can It Really Treat ALD? - Verywell Health - November 19th, 2023
- Doctor Says Living To 120 By End Of Decade Is Possible What's the Secret? - Benzinga - November 19th, 2023
- The week in pharma: action, reaction and insight week to ... - The Pharma Letter - November 19th, 2023
- Race Cannot Be Used To Predict Heart Disease, Scientists Say ... - Slashdot - November 19th, 2023
- SpaceX's Starship Reaches Outer Space Before Intentional ... - Slashdot - November 19th, 2023
- Mesenchymal Stem Cells Market is projected to reach USD 3,319 million by 2030 according to a new research r... - WhaTech Technology and Markets News - November 17th, 2023
- LMRUK: Protecting the next generation through cord blood - Charity Today News - November 17th, 2023
- Anti-aging molecule discovered that extends lifespan - Earth.com - November 17th, 2023
- Montana State researcher envisions living building materials that ... - Montana State University - November 17th, 2023
- OxyHelp Explores the Benefits of Hyperbaric Oxygen Therapy for ... - StreetInsider.com - November 15th, 2023
- Health benefits of bone marrow - Pakistan Observer - November 15th, 2023
- Evolving the standard of care: What is next for functional ... - NeuroNews International - November 15th, 2023
- Affimed Reports Third Quarter 2023 Financial Results and ... - BioSpace - November 15th, 2023
- Meet the World's First Whole-Eye Transplant Recipient - TIME - November 15th, 2023
- Calidi Biotherapeutics Reports Third Quarter 2023 Operating and ... - Business Wire - November 15th, 2023
- 10 Asia-Pacific biotech companies leading innovation in the region - Labiotech.eu - November 15th, 2023
- Fitspresso Reviews (November Update) Natural Ingredients That ... - Bainbridge Island Review - November 15th, 2023
- 2seventy bio Reports Third Quarter Financial Results and Recent ... - Business Wire - November 15th, 2023
- Japan To Create $6.6 Billion Fund To Develop Outer Space Industry ... - Slashdot - November 15th, 2023
- Be The Match, Healthcare Marketing Impact Awards 2023 - Ad Age - November 13th, 2023
- Medicare coverage saves lives. Enrolling shouldn't be this ... - Kevin MD - November 13th, 2023
- Future Ocean Foods: 36 Global Alt-Seafood Startups Form Association To Tackle Overfishing, Microplastics & More - Green Queen Media - November 13th, 2023
- Orchard Therapeutics Reports Third Quarter 2023 Financial Results ... - StreetInsider.com - November 13th, 2023
- Celebrity doctor reveals Hollywoods hidden trend of stem cell antiaging therapies - Longevity.Technology - November 11th, 2023
- Amazon Expands Healthcare Push With One Medical Benefits For ... - Slashdot - November 11th, 2023
- Bene Meat Technologies becomes the first to receive EU approval ... - Pet Food Processing - November 11th, 2023
- FDA Grants Orphan Drug Designation to MAIA Biotechnology for THIO as a Treatment for Glioblastoma - Yahoo Finance - November 11th, 2023
- MaaT Pharma Provides Third Quarter 2023 Business Update and ... - Business Wire - November 11th, 2023
- IN8bio Reports Third Quarter 2023 Financial Results and Provides ... - GlobeNewswire - November 11th, 2023
- Fast Lean Pro Reviews - Overpriced or Optimal Ingredients That ... - Journal of the San Juan Islands - November 11th, 2023
- Fate Therapeutics Reports Third Quarter 2023 Financial Results and ... - GlobeNewswire - November 11th, 2023
- Worlds first whole-eye and partial face transplant gives Arkansas man new hope - CNN - November 9th, 2023
- Glowing Fingertips And Green Eyes: First-of-Its-Kind Monkey ... - ScienceAlert - November 9th, 2023
- 10 Natural Body Scrubs That Exfoliate And Invigorate My Skin - PINKVILLA - November 9th, 2023
- CRISPR Therapeutics Provides Business Update and Reports Third ... - StreetInsider.com - November 9th, 2023
- Fate Therapeutics Reports Third Quarter 2023 Financial Results and ... - StreetInsider.com - November 9th, 2023
- Sight Care Reviews - Overpriced or Worth the Hype? SightCare Pills ... - Journal of the San Juan Islands - November 9th, 2023
- 6 Amazing Health Benefits Of Giloy (Tinospora cordifolia) - WION - November 9th, 2023
- The Global Market for Bispecific Antibody Therapeutics Contract Manufacturing 2023-2030: Driven by Demand for Innovative Therapies and Promising... - November 7th, 2023
Recent Comments